Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 24 July 2014 | By Alexander Gaffney, RAC,
EU regulators say that two emergency contraceptive drugs, levonorgestrel and ulipristal, remain effective for their prescribed purpose "regardless of bodyweight," placating some—but not all—concerns that the drugs might lose effectiveness when taken by women weighing more than 80kg (176 lbs).
In November 2013, Mother Jones broke the news that HRA Pharma, manufacturer of the emergency contraceptive Norlevo, a levonorgestrel-based emergency contraceptive, was updating its packaging to reflect new evidence that the drug begins to lose effectiveness in overweight women, and may lose all effectiveness in women who are obese.
Norlevo is similar to the levonorgestrel-based emergency contraceptive Plan B, which is widely marketed in the US and available over the counter (OTC).
In the wake of the revelations, the US Food and Drug Administration (FDA) said it would review the evidence to determine if labeling changes were needed for levonorgestrel-based emergency contraceptives.
"The FDA is currently reviewing the available and related scientific information on this issue, including the publication upon which the Norlevo labeling change was based," FDA spokeswoman Erica Jefferson reportedly told news outlets in an email. "The agency will then determine what, if any, labeling changes to approved emergency contraceptives are warranted."
Shortly after FDA announced that it would review the efficacy of the medicines, the European Medicines Agency (EMA) announced that it, too, would review marketed emergency contraceptive products to determine if they lost effectiveness in heavier women.
EMA said that data indicated that the drugs lost effectiveness in women weighing more than 75kg, and all effectiveness in women weighing more than 80kg.
However, after a nine-month review, EMA regulators now say that "all the available evidence on the effectiveness of emergency contraceptives" (HRA Pharma's Norlevo and Bayer's Levonelle) have not substantiated their concerns.
"The Agency’s Committee for Medicinal Products for Human Use (CHMP) recommends that these emergency contraceptives can continue to be used in women of all weights as the benefits are considered to outweigh the risks," the regulator wrote in a 24 July 2014 statement.
Which isn't to say that "all the available evidence" was enough to totally invalidate the regulators' concerns.
EMA said that its regulators found that "the data available are too limited and not robust enough to conclude with certainty that contraceptive effect is reduced with increased bodyweight.”
EMA explained that for both medications, some data had indicated reduced effectiveness was correlated with higher body weight, but that the data was "limited" and was countered by data in other studies that did not show evidence of an effect.
"The Committee for Medicinal Products for Human Use (CHMP) recommended that the results of these studies should be included in the product information of emergency contraceptives, but that the current statements on the impact of bodyweight in the product information for Norlevo should be deleted," EMA said in a statement, adding that, "They can continue to be taken regardless of the woman’s bodyweight."
FDA has yet to announce the results of its own investigation into the drug's efficacy.
EMA Statement
Tags: Plan B, Norlevo, Leconorgestrel, Emergency Contraceptive, Levonelle, Ulipristal, Weight
Regulatory Focus newsletters
All the biggest regulatory news and happenings.